GTHX G1 Pharma: Accounting Value per Share

Public company logo of G1 Therapeutics, Inc. (GTHX)

The book value per share determines the liquidation basis for G1 Therapeutics, Inc. (GTHX), whose CDK4/6 inhibition patents create defensive barriers. Revenues are based on the sale of Cosela and partnership royalties. Expansion into Europe and Asia is broadening the network of oncology center clients. The current 0.47 indicator reflects the status of equity, smoothing out market noise for potential buyers.

GTHX - G1 Pharma Book Value of One Share over the range 07/04/2022 - 09/28/2024

Summary analytical data breakdowns for G1 Therapeutics Inc. (GTHX)

- price and consensus price forecast:
Stock Price G1 Pharma|GTHX - Fair Value Consensus
- market capitalization data:
Market Valuation G1 Therapeutics, Inc.|GTHX - Business Value
- book capitalization data:
Book Value per Share G1 Therapeutics|GTHX - Book Value of Business|Market Capitalization to Book Value Ratio g1therapeutics.com|GTHX - Company Assets
- debt and liquidity data:
Debt to Equity G1 Therapeutics, Inc.|GTHX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital G1 Pharma|GTHX - Company Cumulative Debt|Debt to Book Capitalization Ratio G1 Therapeutics, Inc.|GTHX - Company Long-Term Loans and Borrowings|Company Short-Term Debts G1 Therapeutics
Fundamental company valuation:GTHX g1therapeutics.com
Manufactured product of G1 Therapeutics Inc.

This metric reflects the sensitivity of equity to operating losses, measuring the residual value of assets minus liabilities per share. For G1 Therapeutics, Inc. (GTHX), which is depleting reserves on costly R&D without sustainable revenue, the net asset value per share serves as an indicator of the burn rate of its financial foundation and the efficiency of securing external financing.

Competitors of G1 Therapeutics, Inc. (GTHX)

Book Value per Share Incyte Corp. (INCY)|HUTCHMED Corp (HCM) - Accounting Value of a Share|Accounting Value per Share Nuvation Bio Inc.|dayonebio.com (DAWN) - Equity per Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BeyondSpring Inc (BYSI) - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share LIXT|Net Assets per Single Share Citius Pharmaceuticals (CTXR)|Net Assets per Single Share Cellectar Biosciences Inc CLRB|Accounting Value per Share BioLineRx Corp|Can-Fite - Accounting Value of a Share|APRE (Aprea) - Net Assets per Single Share|KZIA: Net Asset Value per Share|Net Assets per Single Share silexion.com|NuCana (NCNA) - Equity per Share|Book Value per Share CMRX|Accounting Value per Share CYCC|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share